NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
Clinical Trials
9 trialsNCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT04022876 2022-10-10
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT00158886 2017-11-14
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT00002948 2014-07-02
High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Yale University
Phase 1 Terminated
NCT01177501 2012-11-19
ITOV04
Assistance Publique - Hôpitaux de Paris
Phase 1 Terminated
NCT00112619 2011-06-30
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
Pediatric Brain Tumor Consortium
Phase 1 Terminated
NCT00322920 2008-02-15
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
University of Alabama at Birmingham
Phase 1 Terminated